$LDOS

Leidos Wins $127M Army ARTEMIS Airborne Intelligence Mission Contract

Leidos secured a $127M Army contract to continue providing the ARTEMIS airborne intelligence system in Europe until 2027, with two option years. The system, operated via a modified Bombardier Challenger 650 aircraft, delivers ISR capabilities. This contract aligns with Leidos' NorthStar 2030 strategy and expands its Defense Tech portfolio.

Original reporting
Published Sep 23, 2026, 4:55 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 6:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$LDOS
Bullish
high confidence
Mentioned
$LDOS
Relevance
9/10
AlphAI data visualization · based on washingtonexec.com
Decision brief

The 30-second read

$LDOSBullishHigh
01

Why it matters

The $127M contract adds to Leidos' defense backlog and may support earnings guidance for FY2027.

02

Market read

New DoD contract likely to lift Leidos' stock modestly and benefit the broader defense sector.

03

What to watch

Potential competition for future phases and reliance on a single platform could limit upside.

Relevance 9/10Novelty 9/10Timing: announcement day

Background

Leidos has been providing the ARTEMIS ISR capability since 2020; the award continues that partnership.

Company-level read

Ticker impact

$LDOSBullishHigh confidence
Context

Leidos secured a new Army contract worth up to $127M for its ARTEMIS ISR system.

Expected impact

Potential modest upside as investors price in additional defense backlog.

Evidence & confidence

Large, multi-year defense contract announced for the first time; market typically reacts positively to new DoD awards.

Market effects

Boosts defense and aerospace sector sentiment, especially ISR and unmanned systems providers.

Positive for U.S. defense contractors operating in Europe and NATO markets.

Reinforces U.S. defense spending narrative amid heightened geopolitical tensions.

Counterpoint

Contract size may be modest relative to Leidos' overall revenue; market may have already priced in the win.

Key entities

  • Leidos

    U.S.-based defense and technology contractor (ticker LDOS).

  • U.S. Army

    Awarding agency for the ARTEMIS ISR contract.

Related articles

$LDOSMedAI 8/10

US Running Low on the 2 Weapons It Would Need Most

The US is reportedly low on air defense interceptors and long-range standoff missiles, according to a defense analyst. The Pentagon's FY 2027 budget plans to increase procurement of these weapons, benefiting companies like Leidos (NYSE:LDOS), Northrop Grumman (NYSE:NOC), Lockheed Martin (NYSE:LMT), RTX (NYSE:RTX), and L3Harris (NYSE:LHX). These companies have seen recent contract wins and revenue growth in defense-related sectors.

$LDOSMedAI 9/10

Leidos to support extended ARTEMIS airborne ISR mission for U.S. Army

Leidos (LDOS) won a $127M U.S. Army contract to extend ARTEMIS airborne ISR mission through 2027, with option years. The contract supports intelligence, surveillance, and reconnaissance operations in Europe and other regions. Leidos provides the aircraft, systems, and services. The contract aligns with Leidos' NorthStar 2030 strategy, expanding its Defense Tech and Mission & Digital Solutions portfolio.

$LDOSMed

Leidos wins $85m Air Force contract for aerospace design

Leidos Inc. secured an $85M contract from the U.S. Department of War for aerospace systems design research, running through 2036. The contract includes vehicle system design and thermal management research, with initial funding of $75,000 from fiscal 2026. Eight companies competed for the contract, awarded by the Air Force Research Laboratory.

$LDOSMedAI 9/10

Infrastructure Acquisition. Is This a Quiet AI Winner?

Leidos (NYSE: LDOS) reported Q3 revenue of $4.6B (+7% YoY) and raised 2026 guidance to $18.2B-$18.4B revenue, $12.20-$12.50 EPS. It acquired ENTRUST for $2.4B, expanding energy infrastructure. Near-term margins may dip due to acquisition costs, but long-term growth is expected from AI data center energy demand.

$AZNHighAI 8/10

AstraZeneca, Leidos, Expeditors International: CNBC ‘Final Trades’ - Expeditors International (NYSE:EXPD)

CNBC's 'Final Trades' featured picks from Jim Lebenthal (AstraZeneca, AZN), Stephen Weiss (Leidos, LDOS), Liz Thomas (Treasuries), and Joseph Terranova (Expeditors, EXPD). AZN reported regulatory approvals and strong trial data, LDOS beat Q2 estimates and raised guidance, and EXPD also exceeded Q2 expectations. Shares of AZN, LDOS, and EXPD rose 2.3%, 3.1%, and 0.5% respectively on Monday.